Amprologix has raised £740,000 in pre-Series A funding round to accelerate the development of novel antibiotics.

Its lead candidate, epidermicin NI01, aims to tackle MRSA infections in hospitals.

The money will be used to complete pre-clinical development of epidermicin NI01 in readiness for Phase I human clinical trials in 2026.